ALPS Medical Breakthroughs ETF (SBIO)
| Assets | $115.57M |
| Expense Ratio | 0.50% |
| PE Ratio | n/a |
| Shares Out | 3.10M |
| Dividend (ttm) | $0.07 |
| Dividend Yield | 0.19% |
| Ex-Dividend Date | Dec 21, 2023 |
| Payout Ratio | n/a |
| 1-Year Return | +23.15% |
| Volume | 6,152 |
| Open | 38.38 |
| Previous Close | 37.82 |
| Day's Range | 38.04 - 38.68 |
| 52-Week Low | 23.21 |
| 52-Week High | 38.80 |
| Beta | 1.06 |
| Holdings | 105 |
| Inception Date | Dec 31, 2014 |
About SBIO
Fund Home PageThe ALPS Medical Breakthroughs ETF (SBIO) is an exchange-traded fund that is based on the S-Network Medical Breakthroughs index. The fund tracks, a market-cap weighted index comprising US-listed biotech companies with one or more drugs currently in either Phase II or Phase III FDA clinical trials. SBIO was launched on Dec 31, 2014 and is issued by SS&C.
Top 10 Holdings
27.06% of assets| Name | Symbol | Weight |
|---|---|---|
| Krystal Biotech, Inc. | KRYS | 4.01% |
| Alkermes plc | ALKS | 3.16% |
| Avidity Biosciences, Inc. | RNA | 2.85% |
| Crinetics Pharmaceuticals, Inc. | CRNX | 2.80% |
| Immunovant, Inc. | IMVT | 2.70% |
| Corcept Therapeutics Incorporated | CORT | 2.42% |
| Merus N.V. | MRUS | 2.40% |
| Denali Therapeutics Inc. | DNLI | 2.29% |
| Arcellx, Inc. | ACLX | 2.23% |
| Xenon Pharmaceuticals Inc. | XENE | 2.20% |
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 21, 2023 | $0.07106 | Dec 27, 2023 |
| Dec 19, 2019 | $0.01585 | Dec 27, 2019 |
| Dec 20, 2018 | $0.78406 | Dec 27, 2018 |
| Dec 21, 2017 | $0.57949 | Dec 28, 2017 |
News
Returns Spiking for This Rate-Sensitive ETF
On the lookout for an ETF that might respond particularly well to rate cuts? One rate-sensitive ETF to watch is seeing returns spike even before rate cuts arrive.
Patent Cliffs Could Spark Wave of Biotech M&A
There's long been talk of a new wave of biotech mergers and acquisitions activity coming to life. In modest amounts, there has been evidence of that playing out.
Big Pharma Has the Firepower for Biotech Deal-Making
In the early innings of 2024, there was a flurry of consolidation in the biotech industry. It stoked hopes that this would finally be the year in which well-heeled blue-chip pharmaceutical companies w...
Vector Space Biosciences (SBIO) Is Now Available for Trading on LBank Exchange
Road Town, Virgin Islands--(Newsfile Corp. - September 24, 2023) - LBank Exchange, a global digital asset trading platform, listed Vector Space Biosciences (SBIO) on September 15, 2023. For all users ...
